Department of Pathology
  Brigham and Women's Hospital
  A teaching Affliate of Harvard Medical School
Login Skip Navigation Links
  Skip Navigation Links
HomeExpand Home





Announcement

Submit new announcement
Petr Jarolim, M.D.,Ph.D.

Associate Professor of Pathology, Harvard Medical School
Director, Clinical Chemistry, Laboratory Control and Ambulatory Care Center Clinical Laboratories, and the Biomarker Research Laboratory/TIMI Clinical Trials Laboratory


Academic Activities:
Clinical trials of newly discovered cardiovascular biomarkers, new applications of established markers of heart disease, molecular genetics of hemolytic anemias and blood group antigens, process improvement by laboratory automation
Office
75 Francis Street
AL-2-215 Amory building
Boston,MA 02115
Email1: pjarolim@partners.org
Education and Training:

Medical School - 1983 : Charles University, School of Medicine, Prague, Czech Republic M.D.
Graduate School - : Charles University, School of Medicine, Prague, Czech Republic Ph.D.
Internship/Residency 7/1/83 - 6/30/85 : Institute of Hematology and Blood Transfusion, The University Hospital, Charles Univ. School of Med.
Residency 07/01/1994 - 06/30/1996 : Brigham and Women's Hospital
Fellowship 07/01/1996 - 06/30/1997 : Brigham and Women's Hospital

Clinical Specialties:
  • Clinical Chemistry
  • Transfusion Medicine
Research Interests:
  • Cardiovascular biomarkers
  • Blood group antigens
  • Laboratory automation
Publication:
  1. Jarolim P, Mircevova L. Changes in fluidity of erythrocyte membranes after storage of erythrocytes and regeneration of cellular ATP level. Biochim Biophys Acta 1982;688:460 4.
  2. Jarolim P, Kinkor M, Haskovec C. Estimation of membrane fluidity of x irradiated human lymphocytes. Radiobiol Radiother 1985;26:299 304.
  3. Plasek J, Jarolim P. Interaction of the fluorescent probe 1,6 diphenyl 1,3,5 hexatriene with biomembranes. Gen Physiol Biophys 1987;6:425 37.
  4. Jarolim P: [Modern fluorescence methods in medical research and clinical practice]. Cas Lek Cesk [J Czech Physicians] 1987;126:65-68.
  5. Marik T, Brabec V, Kodicek M, Jarolim P. Pyruvate kinase deficiency anemia: Membrane approach. Biochem Med Metab Biol 1988;39:55 63.
  6. Jarolim P: [Modern immuno-analytical methods based on fluorescence detection and light scattering]. Cas Lek Ces [J Czech Physicians] 1988;127:65-68.
  7. Plasek J, Cermakova D, Jarolim P. Fluidity of intact erythrocyte membranes. Correction for fluorescence energy transfer from diphenylhexatriene to hemoglobin. Biochim Biophys Acta 1988;941:119 22.
  8. Jarolim P, Palek J, Coetzer TL, Lawler J, Jacob HS, Velez Garcia E, Fradera J, Charles A, Moake JL. Severe hemolysis and red cell fragmentation due to the combination of a spectrin mutation with a thrombotic microangiopathy. Am J Hematol 1989;32:50 6.
  9. Coetzer T, Palek J, Lawler J, Liu S-C, Jarolim P, Lahav M, Prchal JT, Wang W, Alter BP, Schewitz G, Mankad V, Gallanello R, Cao A. Structural and functional heterogeneity of ? spectrin mutations involving the spectrin heterodimer self-association site: Relationship to hematological expression of homozygous HE and HPP. Blood 1990;75:2235 44.
  10. Haskovec C, Lemez P, Neuwirtova R, Wilhelm J, Jarolim P. Differentiation of human myeloid leukemia cell line ML 1 induced by retinoic acid and 1,25 dihydroxyvitamin D3. Neoplasma 1990;37:565 72.
  11. Jarolim P, Lahav M, Liu S C, Palek J. Effect of hemoglobin oxidation products on the stability of red cell membrane skeleton and the associations of skeletal proteins: correlation with a release of hemin. Blood 1990;76:2125 31.
  12. Liu SC, Zhai S, Palek J, Golan DE, Amato D, Hassan K, Nurse G, Babona D, Coetzer T, Jarolim P, Zaik M, Borwein S. Molecular defect of the band 3 protein in Southeast Asian ovalocytosis. New Engl J Med 1990;323:1530 8, 1990.
  13. Jarolim P, Palek J, Amato D, Hassan K, Sapak P, Nurse GT, Rubin HL, Zhai S, Sahr KE, Liu S-C. Deletion in erythrocyte band 3 gene in malaria-resistant Southeast Asian ovalocytosis. Proc Natl Acad Sci USA 1991;88:11022 6.
  14. Jarolim P, Palek J, Rubin HL, Prchal J, Korsgren C, Cohen CM. Band 3 Tuscaloosa: Pro327?Arg327 substitution in the cytoplasmic domain of erythrocyte band 3 protein associated with spherocytic anemia and partial deficiency of protein 4.2. Blood 1992;80: 523 9.
  15. Jarolim P, Rubin HL, Zhai S, Sahr KE, Liu SC, Mueller TJ, Palek J. Band 3 Memphis: A widespread polymorphism with abnormal electrophoretic mobility of erythrocyte band 3 protein caused by substitution AAG?GAG (Lys?Glu) in codon 56. Blood 1992;80:1592-8.
  16. Sahr KE, Coetzer TL, Moy LS, Derick LH, Chishti AH, Jarolim P, Lorenzo F, Miraglia del Guidice E, Iolascon A, Gallanello R, Cao A, Delaunay J, Liu S-C, Palek J. Spectrin Cagliari: an Ala?Gly substitution in helix 1 of ? spectrin repeat 17 that severely disrupts the structure and self-association of the erythrocyte spectrin heterodimer. J Biol Chem 1993;268:22656-62.
  17. Jarolim P, Rubin HL, Liu SC, Cho MR, Brabec V, Derrick LH, Yi SJ, Saad STO, Alper S, Brugnara C, Golan DE, Palek J. Duplication of 10 bases in the erythroid band 3 (AE1) gene in a kindred with hereditary spherocytosis and band 3 protein deficiency (Band 3PRAGUE). J Clin Invest 1994;93:121-30.
  18. Liu S-C, Jarolim P, Rubin HL, Palek J, Amato D, Hassan K, Zaik M, Sapak P. The homozygous state for the band 3 protein mutation in Southeast Asian ovalocytosis may be lethal. Blood 1994;84:3590-1.
  19. Sahr KE, Taylor WM, Daniels BP, Rubin HL, Jarolim P. The structure and organization of the human erythroid anion exchanger (AE1) gene. Genomics 1994;24:491-501.
  20. Jarolim P, Rubin HL, Brabec V, Chrobak L, Zolotarev AS, Alper SL, Brugnara C, Wichterle H, Palek J. Mutations of conserved arginines in the membrane domain of erythroid band 3 lead to a decrease in membrane-associated band 3 and to the phenotype of hereditary spherocytosis. Blood 1995;85:634-40.
  21. Jarolim P, Rubin HL, Palek J. A nonsense mutation 1669 Glu?Ter within the regulatory domain of human erythroid ankyrin leads to a selective deficiency of the major ankyrin isoform (band 2.1) and a phenotype of dominantly inherited spherocytosis. J Clin Invest 1995;94:941-7.
  22. Jarolim P, Rubin HL, Brabec V, Palek J. Comparison of the ankyrin (AC)n microsatellites in genomic DNA and mRNA reveals absence of one ankyrin mRNA allele in 20% of patients with hereditary spherocytosis. Blood 1995;85:3278-82.
  23. Jarolim P, Wichterle H, Hanspal M, Murray J, Rubin HL, Brabec V, Palek J. ? spectrinPRAGUE: a truncated ? spectrin producing spectrin deficiency, defective spectrin heterodimer self-association and a phenotype of spherocytic elliptocytosis. Br J Haematol 1995;91:502-10.
  24. Chernova M, Jarolim P, Palek J, Alper SL. Overexpression of AE1 Prague, but not of AE1 SAO, inhibits wild-type AE1 trafficking in Xenopus oocytes. J Memb Biol 1995;148:203-10.
  25. Wichterle H, Palek J, Hanspal M, Jarolim P. Combination of two mutant ? spectrin alleles underlies a severe spherocytic hemolytic anemia. J Clin Invest 1996,98:2300-2307.
  26. Jarolim P, Murray JL, Rubin JL, Prchal JT, Ballas SK, Snyder ML, Chrobak L, Melrose WD, Brabec V, Palek J. Characterization of thirteen novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 1996;88:4366-4374.
  27. Jarolim P, Murray JL, Rubin HL, Coghlan G, Zelinski T. A Thr552?Ile substitution in erythroid band 3 gives rise to the Warrior blood group antigen. Transfusion 1997;37:398-405.
  28. Rysava R, Tesar V, Jirsa M, Brabec V, Jarolim P. Incomplete distal renal tubular acidosis coinherited with a mutation in the band 3 (AE1) gene. Nephrol Dial Transplant 1997;12:1869-1873.
  29. Brabec V, Palek J, Petrtylova K, Cermak J, Jarolim P: [Relation between types of erythrocyte membrane defects and the clinical picture in hereditary spherocytosis]. Vnitr Lek [Internal Medicine] 1997;43:91-94.
  30. Hassoun H, Vassiliadis JN, Murray J, Njolstad PR, Rogus JJ, Ballas SK, Schaffer F, Jarolim P, Brabec V, Palek J. Characterization of the underlying molecular defect in hereditary spherocytosis associated with spectrin deficiency. Blood 1997;90:398-406.
  31. Jarolim P, Murray JL, Rubin HL, Smart E, Moulds JM. Blood group antigens Rba, Tra, and Wda are located in the third ectoplasmic loop of erythrocyte band 3 protein. Transfusion 1997;37:605-615.
  32. Jarolim P, Shayakul C, Prabakaran D, Jiang L, Stuart-Tilley A, Rubin HL, Simova S, Zavadil J, Herrin JT, Brouillette J, Somers MJG, Seemanova E, Brugnara C, Guay-Woodford L, Alper SL. Autosomal dominant distal renal tubular acidosis is associated in three families with heterozygosity for the R589H mutation in the AE1 (band 3) Cl-/HCO3- exchanger. J Biol Chem, 1998;273:6380-6388.
  33. Jarolim P, Rubin HL, Zakova D, Storry J, Reid ME. Characterization of seven low incidence blood group antigens carried by erythrocyte band 3 protein. Blood, 1998;92:4836-4843.
  34. Shayakul C, Jarolim P, Alper SL: Autosomal dominant distal renal tubular acidosis and the AE1 gene. Am J Kidney Dis 1999;33:1194-1197.
  35. Brabec V, Cermak J, Jarolim P: [Silent forms of hereditary spherocytosis]. Vnitr Lek [Internal Medicine] 1999;45:594-597.
  36. Jarolim P, Seemanova E: [Nijmegen breakage syndrome (NBS)]. Cs Pediat [Czechoslovak Pediatrics] 1999;54:97-101.
  37. Jarolim P, Seemanova E: [Distal renal tubular acidosis – direct detection of mutations in the AE1 gene]. Cs Pediat [Czechoslovak Pediatrics] 1999;54:102-105.
  38. Brabec V, Cermak J, Petrtylova K, Jarolim P: [Pregancy in patients with hereditary spherocytosis]. Vnitr Lek [Internal Medicine] 1999;45:220-223.
  39. Ranganathan V, Heine WF, Ciccone DN, Rudolph KL, Wu X, Chang S, Hai H, Ahearn IM, Livingston DM, Resnick I, Rosen F, Seemanova E, Jarolim P, DePinho RA, Weaver DT: Rescue of a telomere length defect of Nijmegen Breakage Syndrome cells requires NBS and telomerase catalytic subunit. Current Biol 2001;11:962-966.
  40. Rivera A, Jarolim P, Brugnara C: Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002; 99:357-363.
  41. Seemanova E, Seeman P, Jarolim P: [Chromosome instability syndromes]. Cas Lek Cesk [J Czech Physicians] 2002;141:16-22.
  42. Grebenova D, Kuzelova K, Smetana K, Pluskalova M, Cajthamlova H, Marinov I, Fuchs O, Soucek J, Jarolim P, Hrkal Z: Mitochondrial and endoplasmic reticulum stress induced apoptotic pathways are simultaneously activated by 5-aminolevulinic acid-based photodynamic therapy in HL60 leukemia cells. J Photochem Photobiol B:Biol 2003; 69:71-85.
  43. Zachlederova M, Jarolim P: Gene expression profiles of microvascular endothelial cells after stimuli implicated in the pathogenesis of vasoocclusion. Blood Cells Mol Dis, 2003; 30:70-81.
  44. Varo N, Vicent D, Libby P, Nuzzo R, Calle-Pascual A, Bernal MR, Fernández-Cruz A, Veves A, Jarolim P, Varo JJ, Goldfine A, Horton E, Schönbeck U: Elevated plasma levels of the atherogenic mediator sCD40L in diabetic patients: A novel target of thiazolidinediones. Circulation, 2003; 107:2664-2669.
  45. Srinivasa V, Gerner P, Haderer A, Jarolim P, Wang GK: Relative toxicity of amitriptyline, bupivacaine and levobupivacaine in rats by rapid infusion. Anesth Analg, 2003; 97:91-95.
  46. Özcan R, Jarolim P, Lux SE, Ungewickell E, Eber SW: Simultaneous (AC)n microsatellite polymorphism analysis and SSCP screening is an efficient strategy for detecting ankyrin 1 mutations in dominant hereditary spherocytosis. Br J Haematol, 2003; 122:669-677.
  47. Shayakul C, Jarolim P, Zachlederova M, Prabakaran D, Cortez-Campeao, Kalabova D, Stuart-Tilley AK, Ideguchi H, Haller C, Alper SL: Characterization of a highly polymorphic marker adjacent to the SLC4A1 gene and of kidney immunostaining in a family with distal renal tubular acidosis. Nephrol Dial Transplant 2004; 19:371-379.
  48. Foxman EF, Jarolim P: Use of the fetal fibronectin test in decisions to admit to hospital for preterm labor. Clin Chem 2004; 50:663-665.
  49. Jarolim P, Kalabova D, Reid ME: Substitution Glu480Lys in erythroid band 3 corresponds to the Fra blood group antigen and supports existence of the second ectoplasmic loop of band 3. Transfusion 2004; 44:684-689.
  50. Alexander EK, Marqusee E, Lawrence J, Jarolim P, Fischer GA, Larsen PR: Time of onset and magnitude of increase in levothyroxine requirements during pregnancy in women with hypothyroidism. New Engl J Med 2004; 351:241-249.
  51. Dorfman DM, Goonan EM, Boutilier MK, Jarolim P, Tanasijevic M, Goldhaber SZ: Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation. Vascular Medicine 2005; 10:1-5.
  52. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, White HD, Fox KA, Califf RM, Braunwald E, for the A to Z Investigators: Prognostic value of B-type natriuretic peptide during follow-up of patients with unstable coronary artery disease in the A to Z Trial. J Amer Med Assoc 2005; 294:2866-2871.
  53. Zachlederova M, Jarolim P: The dynamics of gene expression in human lung microvascular endothelial cells after stimulation with inflammatory cytokines. Physiol Res 2006; 54:39-48.
  54. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E: Intensive Statin Therapy and the Risk of Heart Failure after an Acute Coronary Syndrome. J Am Coll Cardiol 2006; 47:2326-31.
  55. Cai YH, Alvarez A, Lim Y-C, Jarolim P, Lowe JB, Luscinskas FW, Lichtman AH: Abrogation of functional selectin-ligand expression reduces migration of pathogenic CD8+ T cells into heart. J Immunol 2006; 176:6568-75.
  56. Taqueti VR, Grabie N, Colvin R, Pang H, Jarolim P, Luster A, Glimcher L, Lichtman AH. T-bet controls pathogenicity of cytotoxic T lymphocytes in the heart by separable effects on migration and effector activity. J Immunol 2006; 177:5890-5901.
  57. Melanson SEF, Berg A, Jarolim P, Tanasijevic MJ, McElrath TF: Validation of a formula that calculates the estimated risk of respiratory distress syndrome. Obstet Gynecol 2006; 108:1471-1476.
  58. Jarolim P: Serum biomarkers for heart failure. Cardiovascular Pathology 2006; 15:144-149.
  59. Melanson SEF, Szymanski T, Rogers SO, Jarolim P, Frendl G, Rawn JD, Cooper Z, Ferrigno M. Utilization of arterial blood gas measurements in a large tertiary care hospital. Am J Clin Pathol, Am J Clin Pathol 2007; 127:604-609.
  60. Karmpaliotis D, Ruisi CP, Kirtane AJ, MD, Polonsky T, Jarolim P, Malhotra A, Talmor D, Kosmidou I, Gibson CM, Morrow DA: Diagnostic and prognostic utility of brain natriuretic Peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 2007; 131:964-971.
  61. Melanson SEF, Morrow DA, Jarolim P: Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007; 128:282-286.
  62. Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, Maly J, Smolej L, Zajic J, Masin V, Zimova R, Rehacek V. Elevated serum soluble endoglin (sCD105) decreases during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis. 2008; 197:264-270.
  63. Melanson SEF, Jarolim P, McElrath TF, Berg A, Tanasijevic MJ. Fetal lung maturity testing in diabetic mothers: Utility of TDx-FLM II surfactant-to-albumin assay, disaturated phosphatidylcholine and logistic regression models. LabMedicine 2007; 38:553-55.
  64. Collard CD, Shernan SK, Fox AK, Vaughn WK, Bernig T, Chanock SJ, Takahashi K, Ezekowitz AB, Jarolim P, Body SC: The MBL2 “LYQA secretor” haplotype is an independent predictor of postoperative myocardial infarction in Caucasians undergoing coronary artery bypass graft surgery. Circulation 2007; 116:I106-I112.
  65. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS, Califf RM, Braunwald E: Serial measurement of monocyte chemoattractant protein-1 following acute coronary syndromes: Results from the A to Z trial. J Am Coll Cardiol 2007; 50:2117-2124.
  66. Seemanova E, Jarolim P, Seeman P, Varon V, Digweed M, Swift M, Sperling K: Cancer risk of heterozygotes with the NBN founder mutation. J Natl Cancer Inst 2007; 99:1875-1880.
  67. Melanson, SEF, Lindeman N, Jarolim P: Selecting automation for the clinical chemistry laboratory. Arch Pathol Lab Med 2007; 131:1063-1069.
  68. Melanson, SEF, Tanasijevic MJ, Jarolim P: Cardiac Troponin Assays: A view from the clinical chemistry laboratory. Circulation 2007; 116:e501-e504.
  69. Lindeman NI, Freeto SM, Jarolim P: Immunosuppressant monitoring can be performed by UPLC-Tandem Mass Spectrometry in half the time needed for conventional HPLC-Tandem Mass Spectrometry, with comparable analytical performance. Clin Chim Acta 2008; 388:207-210.
  70. Melanson SE, Conrad MJ, Mosammaparast N, Jarolim P: Implementation of a highly sensitive cardiac troponin I assay: test volumes, positivity rates and interpretation of results. Clin Chim Acta 2008; 395:57-61.
  71. Melanson, SEF, Lindeman N, Jarolim P: How Laboratory Automation Can Help Laboratories, Clinicians, and Patients. LabMedicine 2008; 39:137-143.
  72. Fox AA, Shernan SK, Collard CD, Liu K-Y, Aranki s, DeSantis SM, Jarolim P, Body SC: Preoperative B-type natriuretic peptide independently predicts ventricular dysfunction and mortality after primary coronary artery bypass graft surgery. J Thor Cardiovasc Surg 2008; 136:452-461.
  73. Sabatine MS, Morrow DA, de Lemos JA, Jarolim P, Braunwald E: Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J, 2009; 30:162-9.
  74. Jarolim P: Other protein blood groups. In: Simon TL, Dzik WH, Snyder E, Stowell CP, Strauss RG, eds. Rossi’s Principles of Transfusion Medicine, 3rd edition, Chichester, Blackwell Publishing Ltd. 2009, 121-130.
  75. Gallagher PG, Jarolim P: Red blood cell membrane disorders. In: Hoffman R, Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, eds. Hematology: Basic principles and practice, 5th edition, Philadelphia: Churchill Livingstone Elsevier 2009, 623-643.
  76. Scirica BM, Cannon CP, Sabatine, MS, Jarolim P, Sloan S, Rifai N, Braunwald E, Morrow DA: Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death. Clin Chem 2009; 55:265-73.
  77. Melanson SE, Kredlow MI, Jarolim P: Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective. Clin Chem Lab Med. 2009; 47:971-6.
  78. Morrow DA, Scirica BM, Sabatine MS, de Lemos JA, Murphy SA, Jarolim P, Theroux P, Bode C, Braunwald E. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol 2010; 55:1189 96.
  79. Mahajan VS, Pace CA, Jarolim P: Seroreactivity to HIV antigens in the absence of HIV infection. Clin Chem 2010, in press.
<October 2017>
SuMoTuWeThFrSa
24252627282930
1234567
891011121314
15161718192021
22232425262728
2930311234


<Friday, October 20, 2017>
8:00 AM
Dr. Maria Kuba, Dr. Yi Daniel Li
Cotran Conference Center
9:15 AM

Autopsy suite
12:00 PM

GYN 14-headed scope
1:00 PM
Dr. Christopher Fletcher
Cotran Conference Center
Copyright 2008 - 2017, BWH Pathology, All rights reserved.